Abstract and Introduction
Abstract
Purpose of Review: Several drugs cause nephrotoxicity and accelerate progression of chronic kidney disease (CKD). The objective of this review is to summarize recent evidence on drugs that either increase the risk of nephrotoxicity, progression of CKD or drug induced harm in patients with CKD.
Recent Findings: Bisphosphonates and hypnotics increase the progression of CKD, whereas denosumab does not accelerate progression of CKD. Tenofovir disoproxil fumarate (TDF) increases the risk of renal tubular toxicity and adverse effects on bone, but Tenofovir alafenamide (TAF) and Tenofovir amibufenamide (TMF) have favorable safety profile on the kidneys and bones. Although no dosage adjustment is needed for Oral Nirmatrelvir/Ritonavir in patients with mild renal impairment and coronavirus disease 2019, the dosage is reduced to twice daily in those with moderate renal impairment. It is not recommended in patients with severe renal impairment. The prescribing information does not recommend use of remdesevir below glomerular filtration rate (eGFR) < 30 ml/min but recent studies suggest that remdesevir may be safe and effective in patients with varying levels of CKD severity. Molnupiravir does not require dose adjustment in patients with CKD.
Summary: Several medications increase the risk of development of acute kidney injury or progression of CKD. Close attention is needed to select the appropriate dose or safer alternatives to reduce the risk of drug-induced harm in patients with CKD.
Introduction
The high prevalence of chronic kidney disease (CKD) in the US is attributable to the rising prevalence of diabetes and hypertension. However, there are several drugs which can cause nephrotoxicity and accelerate progression of CKD. An earlier review of studies prior to 2018 highlighted medication safety issues in patients with CKD.[1] Clinicians are familiar with nephrotoxins which cause acute kidney injury (AKI) such as non-steroidal antiinflammtory drugs, aspirin and ibuprofen. Clinicians are already familiar with recent studies on the safety of novel anticoagulants,[2] and the risk of fractures with proton pump inhibitors in CKD.[3,4] The objective of this review is to summarize recent evidence on drugs that either increase the risk of nephrotoxicity, progression of CKD or harms in patients with CKD.
Curr Opin Nephrol Hypertens. 2023;32(5):434-438. © 2023 Lippincott Williams & Wilkins